Utility and timing of Technetium-99m-diethylene-triamine-penta-acetic acid measurement of glomerular filtration rate in patients undergoing peptide receptor radionuclide therapy

#3174

Introduction: Renal toxicity is a potential side effect of Lutetium-177 Peptide Receptor Radionuclide Therapy (177Lu-PRRT). Some centres use serial Technetium-99m-diethylene-triaminepentaacetic acid (99mTc-DTPA) glomerular filtration rate (GFR) measurements to detect early renal toxicity, but there is no consensus regarding the timing of serial scans nor its utility.

Aim(s): We aimed to determine if baseline and mid-course (Post-cycle 2) GFR can predict patients in whom the GFR would fall below 50 mL/min/1.73m2, following all 4 cycles of 177Lu-PRRT. Further, we review the diagnostic yield of 99mTc-DTPA imaging.

Materials and methods: Single-centre retrospective review of GFR results, measured at baseline, mid-course and after 4 cycles (post-completion) of 177Lu-PRRT in patients (August 2013 -December 2018). The 99mTc-DTPA measured GFR corrected for body surface area (GFRcor) was evaluated. 99mTc-DTPA imaging was reviewed to determine the incidence of findings that changed management. R statistical language was used for analysis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Agarwal V, Gordon S, Bailey D, Pavlakis N, Aslani A,

Keywords: Technetium-99m-diethylene-triaminepentaacetic acid (99mTc-DTPA) glomerular filtration rate (GFR), Lutetium-177 Peptide Receptor Radionuclide Therapy (177Lu-PRRT),